Kidney Cancer Association announces consolidation of social media links across the Internet
Researchers found renal cancer cells planted in a supportive environment proliferate with the help of an enzyme usually only seen in the brain.
Adoptive immunotherapy can be a therapeutic option...
Pfizer RxPathways, formerly Pfizer Helpful Answers, is a comprehensive assistance program that provides eligible patients with a range of support services...
A study published in the journal Archives of Internal Medicinehas shown that people who regularly take painkiller drugs like ibuprofen or naproxen are 51 percent more likely to develop kidney cancer.
Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib)
The primary objective of this study was to assess how the tolerability and safety differences between GSK’s Votrient (pazopanib) versus Sutent (sunitinib)...
Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. No vaccine-related serious adverse events were noted and the report presents a hitherto achieved median survival for patients with poor prognosis that clearly exceeds the expected median survival for patients treated with established drugs.
Breaking news from the KCA
In metastatic renal cell cancer (mRCC) patients treated with targeted therapy, baseline hyponatremia is associated with poorer overall survival (OS), time to treatment failure (TTF), and disease control rate (DCR), according to a study published in European Urology.
Sorafenat is the generic alternative to Bayer's Nexavar, and is used to treat a type of kidney cancer called advanced renal cell carcinoma as well as liver cancer.